SCHEMBL14703520

SCHEMBL14703520

CCN(c1cc(Cl)cc(C(=O)NCc2c(C)cc(C)n(C)c2=O)c1C)[C@H]1CC[C@H](N(C)C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 20/20 1.00
▸ EED O75530 1/20 0.69
▸ RBBP4 Q09028 1/20 0.69
▸ SUZ12 Q15022 1/20 0.69
▸ AEBP2 Q6ZN18 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15710511 1.00 EZH2 (1.00) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL17898054 0.92 EZH2 (0.85) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL13467967 0.92 EZH2 (0.84) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL15709941 0.92 EZH2 (0.84) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL15710378 0.91 EZH2 (0.84) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL15731220 0.91 EZH2 (0.84) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL13468502 0.91 EZH2 (0.83) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL15710233 0.91 EZH2 (0.83) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL15710838 0.90 EZH2 (1.00) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL13468079 0.90 EZH2 (0.82) EZH2EEDRBBP4SUZ12AEBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3470396-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2019-04-17 — — EP disclosed
EP-2825161-B1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF EPIZYME INC (US) 2019-01-02 — — EP disclosed
EP-3165520-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme Inc (US) 2017-05-10 — — EP disclosed
US-20170065600-A1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF Epizyme, Inc. 2017-03-09 — — US disclosed
US-20160332969-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2016-11-17 — — US disclosed
EP-2697198-B1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2016-06-08 — — EP disclosed
US-9334527-B2 Inhibitors of human EZH2, and methods of use thereof Epizyme, Inc. (US) 2016-05-10 — — US disclosed
US-9175331-B2 Inhibitors of human EZH2, and methods of use thereof Epizyme, Inc. (US) 2015-11-03 — — US disclosed
US-20140275081-A1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2014-09-18 — — US disclosed
US-20140142083-A1 Substituted Benzene Compounds Epizyme, Inc. (US) 2014-05-22 — — US disclosed
US-20130040906-A1 Inhibitors of Human EZH2, and Methods of Use Thereof Epizyme, Inc. 2013-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275081-A1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF EZH2, DOT1L, PRDM7 EZH2 1/4885EED 12/4885RBBP4 178/4885
US-20170065600-A1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF EZH2, DOT1L, PRDM7 EZH2 1/4885EED 12/4885RBBP4 178/4885
US-20140142083-A1 Substituted Benzene Compounds CYP1B1, TP53, VHL EZH2 2519/4885EED 1592/4885RBBP4 253/4885
US-20130040906-A1 Inhibitors of Human EZH2, and Methods of Use Thereof EZH2, DOT1L, PRDM7 EZH2 1/4885EED 12/4885RBBP4 178/4885
US-20160332969-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL EZH2 2519/4885EED 1592/4885RBBP4 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback